Psyence acknowledges reports on U.S. action to advance Ibogaine research

Psyence Biomedical (PBM) acknowledged recent reports that the U.S. administration is preparing an executive order to further evaluate the safety and therapeutic potential of ibogaine, a naturally occurring compound being studied for its potential in treating post-traumatic stress disorder, addiction, and other serious neurological and mental health conditions. The anticipated executive action reflects growing recognition of the need for rigorous, regulated research into novel therapies, particularly in areas where current treatment options remain limited. “Ibogaine has emerged as a compound of increasing global interest, particularly for its potential to address complex and treatment-resistant conditions,” said Jody Aufrichtig, Chief Executive Officer of Psyence BioMed. “We welcome efforts to advance structured, evidence-based research that can more clearly define its safety, efficacy, and role in clinical care.”